148 related articles for article (PubMed ID: 16413100)
1. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
2. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
[TBL] [Abstract][Full Text] [Related]
3. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
5. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
6. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
7. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.
Jarry A; Masson D; Cassagnau E; Parois S; Laboisse C; Denis MG
Mol Cell Probes; 2004 Oct; 18(5):349-52. PubMed ID: 15294323
[TBL] [Abstract][Full Text] [Related]
8. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
9. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
10. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations.
Jeuken J; van den Broecke C; Gijsen S; Boots-Sprenger S; Wesseling P
Acta Neuropathol; 2007 Aug; 114(2):121-33. PubMed ID: 17588166
[TBL] [Abstract][Full Text] [Related]
11. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
12. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
[TBL] [Abstract][Full Text] [Related]
13. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
14. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS
Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143
[TBL] [Abstract][Full Text] [Related]
15. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
16. Infrequent activation of mitogen-activated protein kinase in human colon cancers.
Sakakura C; Hagiwara A; Shirahama T; Nakanishi M; Yasuoka R; Fujita Y; Inazawa J; Abe T; Kohno M; Yamagishi H
Hepatogastroenterology; 1999; 46(29):2831-4. PubMed ID: 10576355
[TBL] [Abstract][Full Text] [Related]
17. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
18. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
20. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors.
Perren A; Schmid S; Locher T; Saremaslani P; Bonvin C; Heitz PU; Komminoth P
Endocr Relat Cancer; 2004 Dec; 11(4):855-60. PubMed ID: 15613458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
